OXY133 Derivative Synthesis via Single-Container Organometallic Reaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing oxysterol-therapeutic agent derivatives, such as OXY133, face challenges including complex multi-step reactions, low yields, high costs, environmental impact, and safety concerns, making them unsuitable for industrial-scale production and clinical applications.
Innovation Solution
A method involving reacting a pregnenolone derivative with an organometallic compound to form a diol derivative, followed by hydroboration-oxidation and subsequent reaction with a therapeutic agent, allowing for the synthesis of OXY133-therapeutic agent derivatives in a single container with improved yield, safety, and reduced environmental impact.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If complex multi-step chemical reactions with protection and deprotection reagents are used to synthesize OXY133, then the synthesis can be performed, but the yield is very low (less than 30%) and the process is difficult to carry out in a single container
Solution Approach 1:
The patent combines multiple synthesis steps into a single reaction container, eliminating the need for separate protection and deprotection steps. The organometallic reagent directly reacts with the starting material to form the diol derivative in one pot, achieving both process simplification and high yield (>90%).
Solution Approach 2:
The patent uses an organometallic compound as an intermediary reagent that enables direct formation of the diol derivative without requiring traditional protection groups. This intermediary approach allows the reaction to proceed through a different mechanism that avoids the low-yielding protection/deprotection sequence.
2Ease of manufacture
If traditional synthesis methods with multiple reagents are used, then complete synthesis can be achieved, but the cost increases and safety concerns arise
Solution Approach 1:
The patent extracts and eliminates the harmful protection and deprotection reagents from the synthesis pathway. By using a direct organometallic substitution reaction, the method removes the steps that generate waste and pose safety risks, while still achieving complete synthesis of the OXY133 derivative.
Solution Approach 2:
The patent converts the potentially harmful organometallic reagent into a beneficial tool by using it in a controlled, single-step reaction that is more selective and safer than traditional multi-step methods. The organometallic reagent's reactivity, which could be hazardous, is harnessed to achieve high-yielding direct substitution without requiring subsequent deprotection steps.
3Reliability
If recombinant human bone morphogenetic protein-2 (rhBMP-2) is used to promote spine fusion, then bone healing is effective, but the manufacturing complexity and costs increase significantly
Solution Approach 1:
The patent replaces the expensive, complex-to-manufacture rhBMP-2 protein with a small molecule oxysterol derivative (OXY133) that can be synthesized chemically in high yield. This small molecule approach achieves comparable bone healing effectiveness without the manufacturing complexity and high costs associated with recombinant protein production.
Solution Approach 2:
The patent changes the fundamental parameter of the therapeutic agent from a large protein molecule (rhBMP-2) to a small organic molecule (oxysterol derivative). This parameter change enables simpler chemical synthesis, reduced manufacturing complexity, and lower costs while maintaining the osteoinductive function through interaction with cellular receptors.
4Stability of the object's composition
If traditional multi-step synthesis with protection reagents is used, then end groups can be protected during synthesis, but the process requires multiple containers and steps increasing complexity
Solution Approach 1:
The patent merges the end group protection function into the main reaction by using the organometallic reagent's inherent selectivity. The reaction conditions and reagent design ensure that only the intended substitution occurs at the desired position, eliminating the need for separate protection steps and multiple containers.
Solution Approach 2:
The organometallic reagent and reaction conditions are designed to be self-selective, automatically reacting at the correct position without requiring external protection groups. The reaction system self-regulates to achieve the desired product structure in a single step, with the reagent's properties providing the necessary selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the production of OXY133-therapeutic agent derivatives with high yields and improved process safety, suitable for industrial applications, while reducing costs and environmental impact, facilitating their use in promoting osteogenesis and bone healing.
Implementation Method 1
reacting a pregnenolone derivative with an organometallic compound to form a diol derivative
Implementation Method 2
subjecting the diol derivative of formula II to hydroboration-oxidation to form a derivative of the oxysterol
Implementation Method 3
subjecting the diol derivative of formula II to hydroboration-oxidation to form a derivative of the oxysterol
Data Source
AI summary
Oxysterol-therapeutic agent derivatives or OXY133-therapeutic agent derivative compounds and methods of synthesizing the same are provided for use in promoting osteogenesis, osteoinduction and/or osteoconduction. Methods of synthesizing in a single container OXY133-therapeutic agent derivatives having high yields and improved process safety are also provided. Methods for synthesizing OXY133-therapeutic agent derivatives that are stereoselective are also provided.